1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.

2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center

3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan